Skip to main content

Here’s who’s vying to replace Graham Platner as Maine Democratic Senate nominee

▶ Watch Video: Maine Democrats navigating uncharted waters as Graham Platner says he will step down

Washington — Graham Platner’s move to suspend his Senate campaign after a woman accused him of sexual assault has prompted a mad dash in Maine, as Democrats position themselves as possible replacements to take on GOP Sen. Susan Collins in November.  

After Platner officially files paperwork to withdraw, the Maine Democratic Party will have until July 27 at 5 p.m. to select a replacement. The party announced it would hold a nominating convention, with details on the process forthcoming. 

While some have made clear they aren’t interested, including Rep. Jared Golden and actor Patrick Dempsey, a growing list of Democrats are making their interest clear. 

Here’s who’s vying to replace Platner on the ballot:

Shenna Bellows

Maine Secretary of State Shenna Bellows quickly jumped into the race for the Democratic Senate nomination. She said in a social media post she has taken on “tough fights for working people” throughout her career, and added: “I’m not stopping now.”

Bellows, 51, sought the governor’s mansion earlier this year, but she fell short in last month’s Democratic primary. The native of Hancock, Maine, previously served in the state Senate and as executive director of the American Civil Liberties Union of Maine. She is the first woman to serve as secretary of state.

It’s Bellows’ second run for Senate. In 2014, she won the Democratic nomination to challenge Collins, but lost in the general election by almost 37 percentage points.

During her gubernatorial campaign, Bellows advocated for more affordable housing and a statewide freeze on property tax increases for Maine residents, paid for by doubling property tax rates for non-resident homes.

Bellows raised just under $1.8 million during her campaign for governor. Because of Maine’s ranked-choice voting system, Bellows and two other primary candidates — former state Senate President Troy Jackson and former state House Speaker Hannah Pingree — endorsed each other. Pingree ended up winning the Democratic nomination.

Bellows, like most of the candidates now seeking to replace Platner, pushed him to drop out of the race shortly after he was accused of sexual assault. She called the allegations — which Platner has denied — “extremely serious.” She said on X that while Platner “ignited a powerful movement to challenge the status quo, given the seriousness of the allegations, he needs to step down.”

David Costello

A native of Bangor and former government official in Maine and Maryland, David Costello previously ran against Platner for the Democratic Senate nomination, and said that if Platner dropped out, “I’m back in.”

Costello won 8.1% of the vote in last month’s primary, trailing Platner (72.1%) and Maine Gov. Janet Mills (19.2%), who had suspended her campaign but remained on the ballot. He was also the Democratic nominee in the 2024 Maine Senate race, though the winner of that race — incumbent Sen. Angus King, an independent — caucuses with Democrats.

Costello raised just over $30,000 from donors and lent his campaign more than $100,000 during this year’s Senate run.

Valli Geiger 

State Rep. Valli Geiger, a close ally of Platner’s, has indicated interest in replacing him on the ballot. 

The 70-year-old told WMTW that Platner was supporting her bid. But she later clarified that she is one of “several people” who have supported Platner and with whom he was speaking.

A nurse and resident of the coastal town of Rockland, Geiger has served in the state Legislature for three terms.

Troy Jackson

Former state Senate President Troy Jackson also threw his name into the mix and filed with the Federal Election Commission for a Senate exploratory committee. 

Jackson, a fifth-generation logger from the tiny northern Maine town of Allagash, told the Bangor Daily News he is the “best person” to replace Platner. 

The 58-year-old has been active in Maine politics since 2002, serving in the Maine House of Representatives and the Maine Senate, where he was president from 2018 to 2024. 

Before Jackson positioned himself as a potential Senate candidate, he was eyeing the governor seat. He came in third in the Democratic primary this past June after raising around $1 million.

Supported by Platner and independent Sen. Bernie Sanders of Vermont in his gubernatorial bid, Jackson billed himself as a progressive candidate who would focus on affordable housing and lowering property taxes. In an MS NOW interview, Jackson called himself a “pickup truck progressive.”

Jackson and Sanders’ ties go back a decade, with Jackson working on his 2016 presidential campaign. Sanders said Jackson would “stand with working-class families against the enormous power of the monied interests.” Some former Platner allies have argued Jackson should succeed Platner.

Earlier in his political career, Jackson held socially conservative views on some issues, including abortion and same-sex marriage, though he has shifted to the mainstream of the Democratic Party since then and attributed some of his prior stances to the views of his rural northern Maine constituents.

Jackson urged Platner to withdraw, writing on X that there is “no place in our politics for sexual violence.”

Dan Kleban

Dan Kleban, a co-founder of the Maine Beer Company, announced that he’s running to replace Platner, and made it official with an FEC filing.

Kleban, 49, briefly ran for Senate last year before suspending his campaign in October and endorsing Mills. His original campaign was built around Maine’s economy and affordability, combined with environmental issues. Like Platner, Kleban is a newcomer to elected politics, but the craft brewery that he founded with his brother in 2009 is well known.

Since suspending his Senate campaign, he has stayed vocal about Maine’s politics on social media, and he condemned the allegations against Platner, calling them “horrifying and completely disqualifying.”

“Mainers deserve a Senator who will fight for them against the DC establishment while also doing what’s right,” he said.

During his initial Senate run last year, Kleban gave almost $215,000 of his own money to his campaign and raised another $244,000 from donors, according to federal records. He spent almost all of his campaign cash during his run.

Paige Loud

Paige Loud, a 29-year-old social worker, filed to run for Senate shortly before Platner ended his campaign. After he dropped out, Loud wrote on social media that “Mainers deserve more than a hand-picked replacement whose morality only kicked in at the last minute.”

Loud ran in the Democratic House primary for Maine’s 2nd Congressional District last month, coming in fourth place with 10.4% of the vote. She contributed around $30,000 to her own campaign and raised about $17,000.

Nirav Shah

Nirav Shah, the former director of the Maine Center for Disease Control and Prevention, also announced that he’s interested in becoming the Senate nominee, after coming in second in the state’s Democratic gubernatorial primary last month.

“Establishment politicians have failed us,” Shah said on X. “To defeat Susan Collins, we need an outsider who is not afraid to take on the broken system she has spent decades upholding.”

As Maine’s CDC director starting in 2019, Shah navigated the COVID-19 pandemic in the Pine Tree State and has touted the state’s fast vaccine rollout. Shah went on to serve as principal deputy director of the U.S. Centers for Disease Control and Prevention under the Biden administration.

A Wisconsin native, Shah has degrees in law and medicine from the University of Chicago, and previously worked in public health in Illinois and Cambodia.

In his gubernatorial bid, Shah’s platform centered on “fixing housing, funding healthcare, feeding kids, and fueling growth — all while fighting the overreaches of the Trump administration.”

During his gubernatorial campaign, Shah raised more than $1 million. He contributed around $100,000 to his campaign, state campaign finance records show.

Shah — who called for Platner to drop out of the race — said in a campaign launch news conference that there is “very little light” between him and Platner on matters of policy, but he “would not accept an endorsement from Graham, nor have I sought one.”

Shah told CBS News that Maine Democrats are “feeling a thousand emotions all at once” following the allegation against Platner and the campaign shake-up. 

“The one I would say is overriding is the eagerness and the commitment to defeating Susan Collins in the fall,” Shah said. 

Jordan Wood

Jordan Wood, who previously sought the Senate seat last year before dropping out to run in a House race, announced he’s hoping to replace Platner on the ballot. 

Wood, a 36-year-old native of Lewiston, Maine, previously worked as chief of staff to Democratic Rep. Katie Porter before founding an organization focused on combating election denialism. He launched his campaign for Senate last year before pivoting to run for a House seat to replace moderate Democratic Rep. Jared Golden in Maine’s red-leaning 2nd Congressional District, where he fell short last month. 

In a post on X, Wood touted his work to “get big money out of politics and end corruption in Washington.”

“If I am a nominee for Senate, I’ll lead the fight to pass Medicare for All, pass sweeping anti-corruption reform, and stand up to Trump’s lawlessness,” he said.

During his House bid, Wood raised more than $5 million from donors and lent $400,000 to his campaign, the vast majority of which he spent during the campaign, according to FEC data.

La prueba de sangre para el alzhéimer de Roche y Eli Lilly recibe autorización de la FDA

La Administración de Alimentos y Medicamentos de EE.UU. autorizó la prueba de sangre de Roche y su socio Eli Lilly para ayudar a identificar indicios de la enfermedad de Alzheimer en personas de 55 años o más con deterioro cognitivo.La prueba, Elecsys pTau217, es un análisis de sangre de biomarcadores que puede ayudar a los médicos a identificar a los pacientes que probablemente presentan o no cambios cerebrales relacionados con el alzhéimer, informó Roche el lunes.La autorización de la FDA se produce después de que la prueba fuera aprobada en Europa en mayo.La prueba puede realizarse en más de 4.500 analizadores de laboratorio de Roche ya instalados en Estados Unidos, lo que, según la empresa, podría ayudar a ampliar el acceso. Labcorp y Quest Diagnostics dijeron que planean ofrecer la prueba a través de sus redes de laboratorios, lo que podría aumentar su disponibilidad.Roche no reveló el precio de la prueba.La autorización de la FDA se produce mientras los fabricantes de medicamentos y las empresas de diagnóstico compiten por desarrollar pruebas más sencillas para detectar la enfermedad de Alzheimer y satisfacer la creciente demanda de diagnóstico y tratamiento tempranos.Lumipulse, de Fujirebio, se convirtió en 2025 en la primera prueba de sangre autorizada por la FDA para ayudar a evaluar la enfermedad de Alzheimer. La prueba Elecsys pTau181 de Roche y Lilly, que mide una proteína diferente a la de la prueba recién autorizada, también recibió el visto bueno de la FDA el año pasado. La semana pasada, la agencia autorizó la prueba Precivity AD2 de C2N Diagnostics.Tradicionalmente, el diagnóstico del alzhéimer requería procedimientos costosos e invasivos, como tomografías por emisión de positrones o punciones lumbares. Sin embargo, las pruebas de sangre que miden los niveles del biomarcador tau fosforilada 217, o p-tau217, “predicen con gran precisión” la acumulación de placas pegajosas de beta-amiloide en el cerebro, dijo a CNN a principios de este año Rachel Buckley, profesora asociada de neurología de la Facultad de Medicina de Harvard.Las placas amiloides, que causan inflamación y perjudican la comunicación entre las neuronas, pueden acumularse en el cerebro décadas antes de la pérdida de memoria o el deterioro cognitivo, incluso cuando las personas tienen entre 30 y 49 años.A medida que aumentan los niveles de beta-amiloide en el cerebro, ovillos de proteínas llamadas tau comienzan a acumularse dentro de las células cerebrales, lo que hace que las neuronas colapsen y mueran. En algunas enfermedades, como la demencia del lóbulo frontal, que afecta la función ejecutiva en lugar de la memoria, los ovillos pueden acumularse sin la presencia de amiloide.No todas las personas con niveles elevados de amiloide desarrollarán demencia, del mismo modo que tener tau en el cerebro no determina que habrá deterioro cognitivo más adelante en la vida, indicó Buckley.Elecsys pTau217 no está diseñada para utilizarse como una prueba diagnóstica independiente y sus resultados deben interpretarse junto con otra información clínica, indicó Roche.“Las ‘pruebas de sangre para el alzhéimer’ individuales pueden plantear numerosos desafíos, y esta nueva prueba no es diferente”, dijo el lunes a CNN por correo electrónico el doctor Richard Isaacson, investigador en prevención del alzhéimer y director de investigación del Instituto de Enfermedades Neurodegenerativas de Florida.“Al igual que cuando un médico solicita una prueba de colesterol, ¿alguna vez pide una sola prueba? No: solicita un panel de pruebas, y esa es la estrategia que recomiendo para reducir al mínimo la confusión y mejorar la precisión del diagnóstico clínico y de la predicción del riesgo”.Isaacson señaló que la nueva prueba “tiene un valor predictivo negativo suficiente (la probabilidad de que descarte correctamente un diagnóstico de la enfermedad de Alzheimer)”, pero afirmó que “el valor predictivo positivo no es muy bueno”.“Los resultados falsos positivos son un problema en la práctica clínica, por lo que debemos tener cuidado (especialmente con una prueba nueva como esta, que tiene clasificaciones positivas, negativas E indeterminadas)”, escribió. Los problemas con la forma en que se manipulan las muestras o la presencia de otras afecciones médicas, como problemas renales o enfermedades virales, también pueden generar confusión al interpretar los resultados.En lugar de utilizar las pruebas de sangre de p-tau217 y amiloide para el diagnóstico, Isaacson las realiza para buscar indicios de cómo responden las personas al tratamiento y a los cambios en el estilo de vida.Las intervenciones personalizadas en el estilo de vida, como una mejor alimentación, ejercicio, sueño y socialización —combinadas con el control de la insulina, el colesterol y otros factores de riesgo según sea necesario— han reducido los niveles de amiloide y tau en pacientes comprometidos con mejorar su salud.“Las investigaciones ahora muestran que hasta el 45 % de los casos de demencia pueden prevenirse con intervenciones en el estilo de vida, como ejercicio, alimentación, interacción social, entrenamiento cognitivo y control de los factores de riesgo vasculares y metabólicos”, dijo a CNN a principios de este año Laura Nisenbaum, directora científica interina de la Fundación para el Descubrimiento de Fármacos contra el Alzhéimer, que financia investigaciones sobre esa enfermedad.The-CNN-Wire™ & © 2026 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.
Read Next Story